Table 3.

Wave 1 – Wave 2 Change in Availability Outcomes for Four Types of HLPs Controlling for Selection Bias and Intraclass Correlation.

	Inhalants			Prescription Drugs			Non-prescription Drugs			Household Products
	t		OR (95% CI)	t		OR (95% CI)	t		OR (95% CI)	t		OR (95% CI)
HLPs Present in Home
Intercept	.17		1.12(.30, 4.16)	.89		1.71(.52, 5.58)	.54		1.45(.37, 5.66)	.95		2.20(.43, 11.22)
Inv. Mill's Ratio	2.79**		4.38(1.55, 12.36)	.34		1.17(.47, 2.94)	1.65+		2.44(.85, 7.04)	1.80+		3.18(.90, 11.22)
Wave	−4.32**		.44(.308, 0.64)	−4.45**		.54(.41, 0.71)	−2.70**		.65(.47, 0.89)	−1.55		.70(.45, 1.10)
Intraclass Correlation		.07			.11			.16			.04
HLPs Locked Up
Intercept	1.15		3.11 (.45,21.52)	1.43		3.36 (.64,17.67)	1.82		7.95 (.85,74.23)	2.77**		100.35 (3.81,2641.32)
Inv. Mill's Ratio	−3.09**		.08 (.02,.41)	−3.14**		.13 (.04,.46)	−4.18**		.02 (.00,.13)	−4.67**		.00 (.00,.02)
Wave	−1.47		.68 (.41,1.14)	2.22*		1.56 (1.05,2.32)	2.40*		1.86 (1.12,3.08)	−1.73		.39 (.14,1.13)
Intraclass Correlation		.12			.18			.23			.29
HLPs Monitored
Intercept	3.56**		11.77 (3.02,45.83)	3.02**		14.53 (2.55,82.65)	4.29**		26.38 (5.89,118.09)	5.30**		44.41 (10.90,180.99)
Inv. Mill's Ratio	−3.44**		.16 (.06,.45)	−1.45		.37 (.10,1.42)	−2.88**		.18 (.06,.58)	−4.97**		.06 (.02,.19)
Wave	−1.10		.85 (.64,1.13)	.10		1.02 (.67,1.55)	−.52		.92 (.67,1.27)	.19		1.03 (.78,1.35)
Intraclass Correlation		.16			.19			.20			.19

Note:

^**p<.01

^*p<.05

⁺p<.10; df for level one tests range between 595 and 678 and df for level two tests range between 348 and 494.